Notes

Submit COVID symptoms: interesting things with regard to medicine.
in 1 year of follow-up. [J Refract Surg. 2020;36(8)544-550.].
To compare toric intraocular lens (IOL) alignment between femtosecond laser-assisted capsular marking and manual corneal marking.

This study prospectively included 72 consecutive eyes (from 72 patients) with cataract and anterior corneal astigmatism of 1.00 diopter (D) or greater that underwent femtosecond laser-assisted cataract surgery with implantation of a toric IOL. These eyes were randomly categorized into two groups based on the IOL alignment method. The femtosecond laser capsular marking group included 36 eyes with capsular markers using the latest femtosecond laser platform. The manual marking group included 36 eyes with manual corneal markers. The preservation of the markers was assessed. Visual acuity and refractive outcomes, as well as deviation from the target axis, were evaluated.

In the femtosecond laser capsular marking group, all capsular markers were retained for at least 3 months. In the manual marking group, 22.2% of the corneal markers disappeared within 1 month and all markers disaignificantly lower in the femtosecond laser-assisted capsular marking group than in the manual corneal marking group. In addition, the long-term preservation of the capsular marker is helpful in evaluating the rotation of the toric IOL. [J Refract Surg. 2020;36(8)536-542.].
To compare the clinical outcomes of mix-and-match implantation of a diffractive extended depth of focus intraocular lens (IOL) (TECNIS Symfony ZXR00; Johnson & Johnson Vision) and a diffractive bifocal IOL (TECNIS ZLB00 +3.25 diopters [D]; Johnson & Johnson Vision) and bilateral implantation of a diffractive trifocal IOL (AcrySof IQ PanOptix; Alcon Laboratories, Inc).

This prospective comparative study compares the clinical outcomes of patients with age-related cataract undergoing cataract surgery using the IOLs described. Patients were divided into the mix-and-match group and the trifocal group. Assessment included monocular and binocular uncorrected distance visual acuity (UDVA), intermediate visual acuity (UIVA at 60 cm), and near visual acuity (UNVA at 40 cm), uncorrected defocus curves, contrast sensitivity, and reading speed. Quality of vision was measured with the Visual Function Questionnaire (VFQ-25).

A total of 50 patients (25 in each group) were enrolled. At 6 months postoperatively, ion demands. check details [J Refract Surg. 2020;36(8)528-535.].
To describe and evaluate a new monofocal intraocular lens (IOL) designed to improve intermediate vision using a unique refractive technology.

The new monofocal lens is based on a higher order aspheric optic and is designed to improve intermediate vision. Simulated visual acuity from far to -2.00 diopters (D) was calculated using optical bench data. The effect of corneal higher order aberrations (HOAs) on simulated visual acuity, pupil size, and decentration was assessed using realistic computer eye models. The susceptibility to photic phenomena was evaluated by measuring preclinically the intensity of the light distribution in the retinal plane. The new lens design was compared to a standard aspheric monofocal IOL that shares the same platform, material, and primary spherical aberration as the new design.

Simulated defocus curves showed increased simulated visual acuity in the intermediate range compared to a standard aspheric monofocal IOL with comparable distance vision, independently of the pupil size and corneal HOAs. At -1.50 D, the new IOL design provided a gain of approximately 0.1 logMAR, whereas at distance, the difference was less than 0.05 logMAR. The tolerance to decentration was also similar in both designs. Finally, experimental results indicate that the susceptibility to photic phenomena with the new lens design was similar to that of a standard aspheric monofocal IOL.

Preclinical data showed that the new lens design improves intermediate vision while maintaining comparable distance image quality and keeping the same photic phenomena profile as a standard aspheric monofocal IOL. [J Refract Surg. 2020;36(8)520-527.].
Preclinical data showed that the new lens design improves intermediate vision while maintaining comparable distance image quality and keeping the same photic phenomena profile as a standard aspheric monofocal IOL. [J Refract Surg. 2020;36(8)520-527.].
To evaluate the visual outcomes of laser vision correction in adults with myopic and hyperopic amblyopia.

The medical records of patients diagnosed as having amblyopia who underwent laser refractive surgery between February 2013 and October 2017 were retrospectively reviewed. Eyes with amblyopia were analyzed, and the nonamblyopic fellow eyes of the patients who underwent laser vision correction were used as controls. The uncorrected distance visual acuity (UDVA), subjective manifest refraction, and corrected distance visual acuity (CDVA) were analyzed at the 3-month postoperative time point.

This study included 323 eyes of 164 patients. All patients underwent laser in situ keratomileusis (90.1%, 291 eyes) or photorefractive keratectomy (9.9%, 32 eyes). Three months postoperatively, the manifest spherical equivalent was -0.07 ± 0.55 diopters (D) (range -1.75 to +1.30 D) and -0.10 ± 0.54 D (range -2.13 to +1.30 D) in the amblyopia group and fellow eye group, respectively. The percentage of eyes achieving UDVA of 20/20 or better was 16.9% (15 eyes) in the amblyopia group and 61.9% (52 eyes) in the fellow eye group. The percentage of eyes that gained two or more lines of CDVA was 27.9% (24 eyes) in the amblyopia group and 6.2% (5 eyes) in the fellow eye group (P < .01). In the amblyopia group, there was no statistically significant difference in the mean manifest spherical equivalent between the myopic eyes and hyper-opic eyes at any follow-up visit (P = .87, 1 month postoperatively; P = .68, 3 months postoperatively).

Laser vision correction was found to be effective and safe in adult patients with amblyopia. [J Refract Surg. 2020;36(8)511-519.].
Laser vision correction was found to be effective and safe in adult patients with amblyopia. [J Refract Surg. 2020;36(8)511-519.].
Website: https://www.selleckchem.com/products/gw4869.html